TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A histologically established diagnosis of multiple myeloma with evidence of relapse or refractory disease.~* Must have a detectable serum or urine M-Protein by protein electrophoresis that is at least 500 mg/dL (serum) or 1 gm/24 hours (urine), respectively, or serum free light chain level \>100 mg/l for the involved free light chain.~* Must have received at least one (1) prior line of systemic treatment that has included either lenalidomide or thalidomide.~* Must be willing to provide correlative blood samples.~Exclusion Criteria:~* Must not have received an excessive cumulative dose of anthracycline~* No ≥ grade 2 peripheral neuropathy.~* No cytotoxic chemotherapy within 30 days prior to registration for protocol therapy.~* No autologous stem cell transplant within 6 months prior to registration for protocol therapy~* No prior radiation therapy to \> 25% of bone marrow forming bones (i.e., pelvis) within 30 days prior to registration for protocol therapy. See Study Procedures Manual to calculate percent of prior radiation.~* No current corticosteroid therapy in doses greater than 10 mg daily of prednisone (or equivalent) if given for management of co-morbid conditions.~* No known central nervous system involvement by myeloma.~* No poorly controlled intercurrent illness including, but not limited to, ongoing or active infection, poorly controlled diabetes, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social climate that in the opinion of the investigator would limit compliance with study requirements.~* No patients known to be positive for HIV, or active Hepatitis A, B, or C.~* No major surgery within 30 days prior to registration for protocol therapy. Placement of a venous access device within 30 days prior to registration for protocol therapy is allowed.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Bendamustine in combination with bortezomib and pegylated liposomal doxorubicin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Pilot Study Comparing Two Vacuum-wound-dressings for Open Abdomen Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients indicated for open-abdomen-treatment by responsible consultant surgeon where vacuum-technique is judged technically possible~Exclusion Criteria:~* Technical reasons~* unjustified risk-benefit-ratio of manipulations necessary for application of vacuum-pack-technique or abdominal-dressing-technique

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vacuum-pack (Type: EXPERIMENTAL): see Interventions
- Abdominal dressing (Type: ACTIVE_COMPARATOR): see Interventions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nutraceutical Citrulline in Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton pregnancy~* Type 2 diabetes with hemoglobin A1c \<8~* Gestational age at randomization between 14 and 16 weeks based on clinical information~* Maternal age between 14 and 40 years~Exclusion Criteria:~* Chronic hypertension~* Major fetal anomaly~* Fetal demise~* Planned termination of the pregnancy~* Collagen vascular disease (autoimmune disease) on medication~* Renal disease~* Epilepsy or other seizure disorder~* Active or chronic liver disease~* Heart disease, known illicit drug or alcohol abuse during current pregnancy~* Already taking L-citrulline as a supplement (1gram/day or more)

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Citrulline (Type: EXPERIMENTAL): Oral L-citrulline, 3 grams once per day for 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, 3 grams once per day for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib and Capecitabine for First Line Colon Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed, newly diagnosed metastatic colorectal cancer~* Measurable or evaluable disease in which surgical resection with curative intent is not possible~* No adjuvant chemotherapy within 6 months of enrollment~* No prior sunitinib or other receptor tyrosine kinase inhibitors~* 18 years of age or greater~* Anticipated survival of at least 6 months~* Ambulatory with an ECOG performance status of 0 or 1 and able to maintain weight~* Normal organ and marrow function~* Must agree to avoid pregnancy or fathering a child through out study participation~* Ability to understand and willingness to sign a written informed consent document~Exclusion Criteria:~* Chemotherapy or radiotherapy within 6 months of enrollment~* Receiving any other investigational agents~* Known untreated brain metastases, uncontrolled seizure disorders, encephalitis, or multiple sclerosis~* Not able to ingest oral medications with normal absorption from the GI tract~* Uncontrolled hypertension~* History of severe/unstable angina, heart attack, congestive heart failure, transient ischemic attack, or stroke within 6 months of enrollment~* Cardiac dysrhythmias~* History of clinically significant bleeding within the past 6 months, including gross hemoptysis or hematuria, or underlying coagulopathy~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of study enrollment~* Current treatment with therapeutic doses of coumadin~* Concurrent malignancy other than colorectal cancer~* Known dihydropyrimidine dehydrogenase deficiency~* Uncontrolled intercurrent illness including ongoing or active infection or psychiatric illness that would limit compliance with study requirements.~* Pregnant and nursing women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sunitinib and cepecitabine (Type: EXPERIMENTAL): Administration of sunitinib and capecitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥18 years. Eastern Cooperative Oncology Group performance status ≤2 (Karnofsky ≥60%, see Appendix A).~Life expectancy of greater than 3 months~Patients be able to undergo VATS resection as defined below:~* Preoperative Forced Expiratory Volume at one second ≥ 40% predicted~* OR~* Post-operative predicted Forced Expiratory Volume at one second ≥ 0.8 l~* Hg ≥ 8.0~* No evidence of coronary ischemia on stress evaluation Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~Patients with surgery for a prior ipsilateral lung cancer~Patients with known brain metastases~Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. (Patients with HIV are not excluded from this study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound (Type: EXPERIMENTAL): Participants in this study have elected to have surgical resection of non-small cell lung cancer tumors as part of their standard of care. During that surgical procedure, participants will also receive laparoscopic intraoperative ultrasound to assess the thoracic wall lymph nodes as part of the experimental procedure. The ultrasound procedure will add about 15 minutes to the total surgical time. Because it is laparoscopic and utilizes non-ionizing radiation, the risk to the participant is minimal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* intubated and mechanically ventilated on a volume controlled mode~* head injury or other intracranial pathology and compromised cerebral perfusion~* arterial line in place or alternative with continuous pressure monitoring~* SpO2 ≥90%~* mean arterial pressure \>55~* admission to ICU or about to undergo neurosurgery with planned placement of an invasive intracranial pressure monitor~* inclusion presents no significant delays to planned emergent neurosurgery~* prior written informed consent~Exclusion Criteria:~* cardiac or pulmonary injury~* confirmed pneumothorax or hemothorax~* serious neck injury resulting in neck swelling with jugular venous compression~* evidence of ongoing uncontrolled bleeding~* respiratory disease such as COPD, interstitial lung disease, or other parenchymal or pulmonary vascular disease~* marked hypertension at time of device use defined as systolic blood pressure \>180 mmHg~* congestive heart failure~* women with positive serum or urine pregnancy test or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ITPR (Type: EXPERIMENTAL): Use of the ITPR for 120 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Contribution of Narrow Band Imaging (NBI) for the Characterization of Scalloped Polyps (NBI POLYPES COLIQUES)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Pre-inclusion criteria:~* Major patient with a colonoscopy scheduled in one of the participating hospitals (CHD Vendée and CHU Nantes).~* Patient who agreed to participate in the study and gave his express consent~* Patient affiliated with a social security system or beneficiary of a scheme~Inclusion Criteria:~* Patient with 1 or more polyps less than 20 mm observed during colonoscopy~Exclusion Criteria:~* Patient with an emergency colonoscopy for ongoing digestive bleeding or occlusion symptoms~* Patient with chronic inflammatory bowel disease (IBD): Crohn's disease or unclassified colitis~* Patient with familial adenomatous polyposis~* Pregnant or lactating woman~* Minor patient~* Major patient under tutorship, curatorship, or deprived of liberty~* Patient unable to understand protocol and / or give express consent~* Patient not affiliated with a social security system or beneficiary of such a scheme~* Patient hospitalized or treated without their consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Colonoscopy with NBI (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Voluntarily provided informed consent~* Meet diagnostic criteria for idiopathic Parkinson's Disease~* On L-Dopa and oral ropinirole~* If female of child-bearing potential, willing to practice contraception from time of informed consent to Follow-Up Visit~Key Exclusion Criteria:~* Pregnant, breastfeeding, or planning to become pregnant~* Active epilepsy within the past year~* Severe dementia or cognitive impairment~* Donated or lost \> 400 mL of blood within 1 month prior to Screening~* History of alcohol or substance use disorder within the prior 12 months~* Recent episodes of moderate to severe dizziness or syncope~* Definite or suspected hypersensitivity to ropinirole or ethylene vinyl acetate~* Used any other investigational drug within 60 days or 5 half-lives prior to Screening, or plan to take any such drug any time during the study

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Requip; One Ropinirole Implant
- Cohort 2 (Type: EXPERIMENTAL): Requip; Two Ropinirole Implants
- Cohort 3 (Type: EXPERIMENTAL): Requip; Three Ropinirole Implants
- Cohort 4 (Type: EXPERIMENTAL): Requip; Four Ropinirole Implants

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a clinically suspected PE (defined as an acute onset of new or worsening shortness of breath, chest pain, hemoptysis, presyncope, or syncope) without another obvious apparent cause.~* High pretest clinical probability of PE or a non-high pretest clinical probability but a positive D-Dimer test.~Exclusion Criteria:~* Age less than 18 years~* Patients with already confirmed PE~* Patients with a clinically suspected high-risk pulmonary embolism (hypotension or shock)~* Use of therapeutic doses of anticoagulants for more than 48 hours~* Other indication for long-term use of anticoagulants~* Contraindication to contrast media (including renal insufficiency with a creatinine clearance lower than 30 ml/min)~* Life expectancy less than 3 months~* Unable/unwilling to give informed consent~* Unlikely to comply with study follow-up~* Ongoing pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Planar V/Q-based strategy (Type: ACTIVE_COMPARATOR): Control arm
- CTPA-based strategy (Type: ACTIVE_COMPARATOR): Control arm
- V/Q SPECT-based strategy (Type: EXPERIMENTAL): Experimental arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Venous Access for Pacemaker and Defibrillator Implants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned pacemaker or implantable defibrillator surgery with at least one new transvenously placed lead.~Exclusion Criteria:~* Difficult vascular access known before surgery, where special access technique is planned or required.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound guided venous access (Type: EXPERIMENTAL): Vascular access of the axillary vein will be performed using an ultrasound system (Siemens Acuson Freestyle) with a wireless vascular ultrasound probe (L8-3 or L13-5). One or more vascular punctures will be performed, as needed.
- Standard of care (Type: NO_INTERVENTION): Vascular access of the axillary or subclavian vein will be performed using anatomical landmarks, fluoroscopy and/or injection of X-ray contrast in the antecubital vein, at the choice of the implanter. One or more vascular punctures will be performed, as needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ARFI Imaging for Targeted Prostate Biopsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men who are scheduled to undergo ultrasound fusion-MR prostate biopsy;~* Men who are willing to participate in the study;~* Subjects must freely sign informed consent to enroll in the study;~* Assessing eligibility: eligibility for the study will be assessed, based upon the above criteria, by the participating urologist at the time of consultation.~* 18 years or older~Exclusion Criteria:~* Men who have had previous treatment for PCa including radiation, cryoablation, chemotherapy, surgery, high intensity focused ultrasound (HIFU), laser therapy or hormone therapy;~* Men who have had previous non-pharmacological invasive or minimally invasive treatment for benign prostatic hypertrophy (BPH) (i.e., TURP, TUMPT, WIT, TUNA, etc);~* standard pharmacological treatment of BPH is allowable~* Men who are mentally impaired and cannot give written consent;~* Men with anomalies of the rectum.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acoustic radiation force impulse (ARFI) (Type: EXPERIMENTAL): Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.
- MR-ultrasound fusion (Type: ACTIVE_COMPARATOR): Patients with suspected PCa who are scheduled to undergo an ultrasound fusion-MR prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of NF2 by National Institutes of Health (NIH) criteria~* Age ≥ 16 years~* Progressive VS growth during the previous 12 months.~* WHO performance status \> or = 2~* Adequate bone marrow, liver and renal function.~* For women of childbearing potential, no pregnancy or breast-feeding~* Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.~* Willingness to provide informed consent~Exclusion Criteria:~* Inability to tolerate periodic MRI scans or gadolinium contrast.~* Inability to tolerate periodic audiologic testing or to understand a language with established scoring for word recognition testing.~* Inability to adequately perform volumetric measurement of at least 1 target lesionNote: Patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed.~* Radiation therapy for the target lesion in the 60 months preceding inclusion in the study.~* Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug.~* Immunization with attenuated live vaccines within one week of study entry or during study period.~* Presence of a fungal infection requiring systemic antifungal treatment at enrollment~* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.~* Patients who have any severe and/or uncontrolled medical conditions.~* Patients with a known hypersensitivity to everolimus or other types of rapamycin or to its excipients.~* Patients unwilling to or unable to comply with the protocol

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RAD001 Treatment (Type: EXPERIMENTAL): All subjects will be given RAD001 for 1 year (12 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues